Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the transaction, the chief financial officer now directly owns 95,679 shares of the company's stock, valued at $5,862,252.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.02, for a total transaction of $552,160.00.

Vaxcyte Trading Up 1.3 %

Shares of NASDAQ:PCVX traded up $0.77 on Monday, reaching $61.60. 627,167 shares of the company's stock were exchanged, compared to its average volume of 836,746. Vaxcyte, Inc. has a twelve month low of $41.57 and a twelve month high of $82.04. The company has a fifty day moving average of $69.09 and a 200-day moving average of $61.21. The company has a market capitalization of $6.70 billion, a price-to-earnings ratio of -14.92 and a beta of 0.89.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the previous year, the business earned ($0.73) earnings per share. As a group, equities research analysts forecast that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a report on Friday, January 12th. Needham & Company LLC reiterated a "buy" rating and set a $95.00 target price on shares of Vaxcyte in a research note on Wednesday, April 10th. Finally, Bank of America boosted their price target on Vaxcyte from $67.00 to $80.00 and gave the company a "buy" rating in a research note on Tuesday, January 2nd. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $78.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PCVX. Raymond James & Associates raised its holdings in shares of Vaxcyte by 28.7% during the 1st quarter. Raymond James & Associates now owns 66,332 shares of the company's stock worth $4,531,000 after buying an additional 14,779 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Vaxcyte by 109.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company's stock worth $3,237,000 after acquiring an additional 24,785 shares during the last quarter. Banque Cantonale Vaudoise boosted its stake in shares of Vaxcyte by 96.7% in the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company's stock valued at $81,000 after purchasing an additional 582 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Vaxcyte by 25.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company's stock valued at $439,000 after purchasing an additional 1,411 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Vaxcyte by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company's stock worth $530,809,000 after purchasing an additional 168,125 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.